Labiotech.eu

cancer dna damage repair duke street bio parp

News and Trends 25 May 2022

Duke Street Bio enters stage with next-generation cancer therapies

The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […]

May 25, 2022 - 3 minutesmins - By Susannah Rodgers

Inside Labiotech 25 May 2022

Labiotech goes global

The past few months have been very exciting for our team. Following our recent acquisition by Inova, we’ve been working hard on defining the future of Labiotech. From our humble beginnings in France to our expansion into the European market, we’ve always been keen to explore new horizons for the benefit of our readers. Once […]

May 25, 2022 - 3 minutesmins - By Joachim Eeckhout

News and Trends 24 May 2022

Vaccines mobilized to control monkeypox outbreak

An unusual outbreak of monkeypox is causing concern worldwide in the shadow of the destructive Covid-19 pandemic. Both old and emerging vaccine technology could aid the fight against the outbreak. In the wake of the world-changing Covid-19 pandemic, the World Health Organization (WHO) is voicing alarm over another unusual outbreak, this time of the viral […]

May 24, 2022 - 5 minutesmins - By Jonathan Smith

In Depth 23 May 2022

The coming of age of European synthetic biology

Within a few years, synthetic biology has evolved from being a new player in the molecular biology and biotech arena to being a front-row contender with multiple industrial advances and large amounts of investor money. There have been a number of definitions of synthetic biology, also known as synbio. Generally, it involves redesigning genetic systems […]

May 23, 2022 - 8 minutesmins - By Helen Albert

glucagon zealand pharma diabetes insulin immunotherapy

News and Trends 20 May 2022

Zealand Pharma’s drug for rare metabolic disease smashes phase III

After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […]

May 20, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 19 May 2022

Evotec, Sernova in partnership to develop beta cell diabetes therapy

Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […]

May 19, 2022 - 3 minutesmins - By Susannah Rodgers

News and Trends 19 May 2022

F2G enlists Shionogi to bring antifungal treatment to Europe and Asia

The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia. The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly […]

May 19, 2022 - 4 minutesmins - By Jim Cornall

Inside Labiotech 19 May 2022

Meet the Future Makers of Labiotech

Following our recent acquisition by Inova, our team is expanding! We’re very excited to welcome three new hires to join our international team: Jim, former Editor at DairyReporter, is joining us as Editor-in-Chief. As a music composer, photographer, and podcaster, he is looking to bring in loads of creative energy and explore fun ways to […]

May 19, 2022 - 8 minutesmins - By Yi-Jen Chang

News and Trends 17 May 2022

US Giant Apollo Bags Billion-Euro Partnership with Sofinnova

As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing the trend for transatlantic deals between biotech investors, the US asset manager Apollo has entered into a billion-Euro partnership with the European venture capitalist (VC) […]

May 17, 2022 - 3 minutesmins - By Anita Chakraverty

News and Trends 16 May 2022

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing marketing authorization from the UK’s drug regulator in April this year, Valneva is struggling to gain traction with its Covid-19 vaccine in the […]

May 16, 2022 - 3 minutesmins - By Jonathan Smith

Opinion 16 May 2022

CRISPR Can Help The Switch To Sustainable Cosmetics

The cosmetics industry is looking for greener ingredients as consumers demand more sustainable products. According to Jon Kratochvil at ERS Genomics, which licenses out patents belonging to the gene editing pioneers Emmanuelle Charpentier and Jennifer Doudna, CRISPR-Cas9 could one day meet the demand for alternatives. The global cosmetics industry is worth more than €480B ($500B), […]

May 16, 2022 - 5 minutesmins - By External Contributor

News and Trends 13 May 2022

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […]

May 13, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Duke Street Bio enters stage with next-generation cancer therapies

Labiotech goes global

Vaccines mobilized to control monkeypox outbreak

The coming of age of European synthetic biology

Zealand Pharma’s drug for rare metabolic disease smashes phase III

Evotec, Sernova in partnership to develop beta cell diabetes therapy

F2G enlists Shionogi to bring antifungal treatment to Europe and Asia

Meet the Future Makers of Labiotech

US Giant Apollo Bags Billion-Euro Partnership with Sofinnova

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

CRISPR Can Help The Switch To Sustainable Cosmetics

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!